Reuters logo
BRIEF-Cannimed Therapeutics Q3 loss from cont ops $0.06 per share​
September 11, 2017 / 11:36 AM / 2 months ago

BRIEF-Cannimed Therapeutics Q3 loss from cont ops $0.06 per share​

Sept 11 (Reuters) - Cannimed Therapeutics Inc:

* Cannimed Therapeutics Inc. reports financial results for Q3 2017

* Cannimed Therapeutics Inc - ‍for three months ended July 31, 2017, company recorded loss from continuing operations of $1.4 million, or $0.06 per share​

* Cannimed Therapeutics-with current, planned cap ex, co is targeting production expansion estimated to reach 17,000 to 21,000 kg within next 24 months​

* Q3 sales rose 80 percent to C$4.8 million Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below